Advances in bispecific biologic therapies for solid tumors and hematological cancers

In an interview with Pharm Exec associate editor Don Tracy, Pedro Valencia, vice president of solid tumor pipeline strategy and execution at AbbVie, talks about how AbbVie is advancing the development of bispecific biologic therapies in both solid tumors and blood cancers.